Clinical trials: Restless Legs Syndrome (RLS)
Restless Legs Syndrome (RLS)
Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia
Treatment Phase I and II Primary Objective: To evaluate the efficacy and safety of FCM (750 mg dose x 2) for treatment of Restless Legs Syndrome (RLS) in patients with iron-deficiency anemia (IDA).
- Trial name
- NCT02826681
- Testing
- Injectafer® (Ferric Carboxymaltose - FCM)
- Where
- 8 sites in United States
- Volunteers
- 70 people
- Sponsor
- American Regent, Inc.
Elderly, Restless Leg Syndrome (RLS)
Effects of PNF Stretching vs Conventional Physical Therapy on the Symptoms of Restless Leg Syndrome in Elderly Population.
Restless leg Syndrome (RLS) is a common condition in the elderly population,characterized byan uncontrollable urge to move the leg,often occuring in the evening or at night,which can significantly disturb sleep and daily…
- Conditions
- Elderly, Restless Leg Syndrome (RLS), Proprioceptive Neuromuscular Facilitation, Sleep Disturbance
- Trial name
- NCT06747741
- Testing
- PNF stretching(Contract relax with agonist contraction), Conventional physical therapy
- Where
- Pakistan
- Volunteers
- 24 people
- Sponsor
- Foundation University Islamabad
Restless Legs Syndrome (RLS)
A Study of Oral Dosing of Gabapentin Enacarbil in Japanese Restless Legs Syndrome Patients
The objective of this study was to assess the efficacy of once-daily oral administration of gabapentin enacarbil versus placebo, based on the change in International Restless Legs Syndrome Rating Scale (IRLS) score in…
- Trial name
- NCT03053427
- Testing
- Gabapentin enacarbil
- Where
- 46 sites in Japan
- Volunteers
- 375 people
- Sponsor
- Astellas Pharma Inc
Restless Legs Syndrome (RLS)
Post-marketing Study of Gabapentin Enacarbil to Evaluate the Effect in Restless Leg Syndrome (RLS) Patients With Moderate Renal Impairment
To evaluate the safety, efficacy and pharmacokinetics of gabapentin enacarbil in moderate to severe primary RLS patients with moderate renal impairment and to confirm dosage and administration in such population.
- Trial name
- NCT01981941
- Testing
- Gabapentin enacarbil
- Where
- 5 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Astellas Pharma Inc
Restless Legs Syndrome (RLS)
Placebo-Controlled Study to Investigate the Efficacy & Safety of Injectafer in the Treatment of RLS
This will be a Phase III, double blinded, multi-center, randomized, placebo-controlled study. Eligible subjects will be randomized in a 1:1 ratio to receive Injectafer or Placebo on days 0 and 5.
- Trial name
- NCT02397057
- Testing
- Injectafer
- Where
- 19 sites in United States
- Volunteers
- 209 people
- Sponsor
- American Regent, Inc.
RLS
An Efficacy and Safety Evaluation of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
The primary objective of the trial is to evaluate the efficacy of HORIZANT 300 mg and 600 mg, compared to placebo, at 12 weeks of treatment, for the treatment of Restless Legs Syndrome (RLS) in adolescents (13 to 17 years of age)…
- Trial name
- RLS (NCT02560766)
- Testing
- HORIZANT 300 mg, HORIZANT 600 mg
- Where
- 12 sites in United States
- Volunteers
- 132 people
- Sponsor
- XenoPort, Inc.
RLS
An Extension Study to Evaluate the Efficacy and Safety of HORIZANT in Adolescents With Moderate-to-Severe Primary RLS
The objectives of the trial are to evaluate the long-term efficacy and safety of HORIZANT (Gabapentin Enacarbil) 600 mg daily, for the treatment of RLS in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe…
- Trial name
- RLS (NCT02633683)
- Testing
- HORIZANT 600 mg
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- XenoPort, Inc.
RLS
A PK and Safety Evaluation of HORIZANT (Gabapentin Enacarbil) in Adolescents With Moderate-to-Severe Primary RLS
The primary objective is to assess the pharmacokinetics (PK) of gabapentin following the single-dose administration of HORIZANT (Gabapentin Enacarbil) in adolescents (13 to 17 years of age) diagnosed with moderate-to-severe…
- Trial name
- RLS (NCT02633657)
- Testing
- HORIZANT 300 mg
- Where
- 4 sites in United States
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome)
This is a multi-center, Phase III study to evaluate the safety and tolerability of proposed dose conversion recommendations for RLS subjects converting from ropinirole immediate release to ropinirole controlled-release for RLS.
- Trial name
- NCT00256854
- Testing
- Ropinirole IR 1 mg, Ropinirole IR 2 mg, Ropinirole CR 2 mg
- Where
- 30 sites in United States
- Volunteers
- 135 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome (RLS)
Effect of Rotigotine Patch Treatment on Cardiovascular Markers in Idiopathic Restless Legs Syndrome
Several studies report association between restless legs syndrome (RLS), HTA and cardiovascular diseases . The mechanisms involved in this relationship remained unknown, but several evidences favor the role of periodic limb…
- Trial name
- NCT01823770
- Testing
- Rotigotine
- Where
- France
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Restless Legs Syndrome (RLS)
Intravenous (IV) Iron Preparation (VIT-45) in the Treatment of Restless Legs Syndrome (RLS)
The purpose of this study was to evaluate the safety of 2 dosage regimens of Intravenous (IV) iron Ferric Carboxymaltose (FCM) in comparison to placebo in patients with Restless Legs Syndrome (RLS)
- Trial name
- NCT01382901
- Testing
- Ferric Carboxymaltose (FCM)
- Volunteers
- 45 people
- Sponsor
- American Regent, Inc.
Restless Legs Syndrome (RLS)
Efficacy of Tyrosine in Restless Legs Syndrome
Tyrosine is a non essential amino acid that is the precursor of the neurotransmitter, dopamine. Tyrosine is converted into Levodihydrophenylalanine (L-Dopa) and L-Dopa is subsequently and avidly converted into dopamine.
- Trial name
- NCT01494766
- Testing
- L-Tyrosine
- Where
- United States
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- Seton Healthcare Family
Restless Legs Syndrome (RLS), Restless Legs Syndrome
12-week Polysomnography Study of Ropinirole Controlled Release for Restless Legs Syndrome
The purpose of this study is to assess the efficacy and safety of ropinirole CR-RLS in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance and period limb movements during sleep.
- Trial name
- (CR-RLS) (NCT00373542)
- Testing
- ropinirole CR-RLS
- Where
- 45 sites in United States
- Volunteers
- 39 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
RLS In Adults: Comparing Immediate Release Formulation With Extended Release Formulation Of Ropinirole
Restless Legs Syndrome (RLS) study in adults comparing immediate release ropinirole with extended release ropinirole over 12 weeks
- Trial name
- NCT00314860
- Testing
- ropinirole Extended Release (XR)
- Where
- 91 sites in United States, Australia and 11 more
- Volunteers
- 568 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome (RLS), Restless Legs Syndrome
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
A 14-Week clinical research study to compare the effectiveness and safety of ropinirole and placebo (an inactive sugar pill) in the treatment of patients with Restless Legs Syndrome (RLS) in the United States.
- Trial name
- NCT00363857
- Testing
- Ropinirole
- Where
- 49 sites in United States
- Volunteers
- 360 people
- Sponsor
- GlaxoSmithKline
Restless Legs Syndrome, Restless Legs Syndrome (RLS)
Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance
The purpose of this study is to assess the efficacy and safety of GSK1838262 extended release tablets in the treatment of patients with Restless Legs Syndrome and associated sleep disturbance.
- Trial name
- NCT00748098
- Testing
- GSK1838262 Extended Release Tablets
- Where
- 24 sites in United States
- Volunteers
- 136 people
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome (RLS)
Study to Assess the Effect of Gabapentin Enacarbil on Simulated Driving in Healthy Subjects
This is a double-blind, placebo-and active-controlled 3-period crossover study designed to assess the effect of GEn 600 mg on simulated driving performance in healthy volunteers.
- Trial name
- NCT01411124
- Testing
- gabapentin enacarbil, diphenhydramine
- Where
- United States
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- XenoPort, Inc.
Restless Legs Syndrome, Moderate to Severe Idiopathic Restless Legs Syndrome (RLS)
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
Ropinirole has shown to improve mood in depressed patients as well as to improve the symptoms of Restless Legs Syndrome. Up to 40% of RLS patients suffer from mild depression, therefore it would be important for decisions no…
- Trial name
- NCT00357097
- Testing
- Ropinirole
- Where
- 50 sites in Germany
- Volunteers
- 240 people
- Sponsor
- GlaxoSmithKline